Literature DB >> 12001999

The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?

Andrew McMichael1, Tomâs Hanke.   

Abstract

The rationale for developing anti-HIV vaccines that stimulate cytotoxic T-lymphocyte responses is given. We argue that such vaccines will work, provided that attention is paid to the development of memory T-cell responses that are strong and preferably activated. Furthermore, the vaccine should match the prevailing virus clade as closely as possible. Vaccines will have to stimulate a wide range of responses, but it is not clear how this can be achieved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001999     DOI: 10.1038/nri779

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  29 in total

1.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

2.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

3.  Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection.

Authors:  Miles P Davenport; Ruy M Ribeiro; Alan S Perelson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

4.  Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa.

Authors:  Igor M Belyakov; Vladimir A Kuznetsov; Brian Kelsall; Dennis Klinman; Marcin Moniuszko; Michael Lemon; Phillip D Markham; Ranajit Pal; John D Clements; Mark G Lewis; Warren Strober; Genoveffa Franchini; Jay A Berzofsky
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

5.  Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity.

Authors:  Jorge R Almeida; Delphine Sauce; David A Price; Laura Papagno; So Youn Shin; Arnaud Moris; Martin Larsen; Gianfranco Pancino; Daniel C Douek; Brigitte Autran; Asier Sáez-Cirión; Victor Appay
Journal:  Blood       Date:  2009-04-23       Impact factor: 22.113

Review 6.  Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

7.  Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).

Authors:  Rajesh Ringe; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines       Date:  2013-07

Review 8.  Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.

Authors:  R Servín-Blanco; R Zamora-Alvarado; G Gevorkian; K Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2016-06-13       Impact factor: 3.452

9.  CD8+ T cells as a source of IFN-γ production in human cutaneous leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Hossein Keshavarz; Rosita Edalat; Abdolfattah Sarrafnejad; Tahereh Shahrestani; Fereidoun Mahboudi; Ali Khamesipour
Journal:  PLoS Negl Trop Dis       Date:  2010-10-12

Review 10.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.